More

    Warning: Illegal string offset 'sidebar' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 498

    Warning: Illegal string offset 'home' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 498

    Warning: Illegal string offset 'home' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 500

    Warning: Illegal string offset 'home' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 504

    Warning: Illegal string offset 'sidebar' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 516

    Warning: Illegal string offset 'home' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 516

    Warning: Illegal string offset 'home' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 518

    Invex secures European patent for Exenatide

    Invex Therapeutics (ASX:IXC) has been granted a European patent for the use of Exenatide in Hydrocephalus, which is a neurological disorder associated with an increased volume of cerebrospinal fluid within the cerebral ventricles. 

    The patent provides additional claims for the use of Exenatide and other GLP-1 receptor agonists in reducing elevated intracranial pressure (ICP) associated with the treatment of hydrocephalus, normal pressure hydrocephalus or meningitis.

    Invex notes that the granting of the patent will be published on 13 December 2023 in the European Patent Bulletin under number EP4000630. 

    Invex Therapeutics Executive Director Thomas Duthy says: “We are pleased to be granted this additional European patent, which further extends the protection of Exenatide across multiple human diseases associated with raised ICP.”

    this additional European patent … further extends the protection of Exenatide across multiple human diseases associated with raised ICP”

    Invex is a biopharmaceutical company focused on the repurposing of approved drug Exenatide.

    Write to Aaliyah Rogan at Mining.com.au

    Images: Invex Therapeutics
    Aaliyah Rogan
    Aaliyah Rogan
    Recently relocated from a small town in New Zealand to Queensland Australia, Aaliyah Rogan is a fervent journalist who recently completed a Communications/Media degree at Otago University. Aaliyah hopes to excel as a journalist and become an inspiration to others.